Literature DB >> 22438785

Mesothelioma: a review.

Frank E Mott1.   

Abstract

Mesothelioma is an insidious disease with long latency after asbestos exposure. New cases are continually diagnosed, although levels are declining with recognition of the asbestos risk and efforts to remove asbestos from the workplace. Treatment for early stage disease with surgery and radiation is potentially curative, but many patients either are too ill to undergo aggressive surgery or present with advanced disease. Chemotherapy with cisplatin and pemetrexed is considered standard, although relapse is common. Second-line therapy is disappointing. New targeted therapies may pose promise and are being addressed in various clinical trial settings. Palliative care remains an important component of the management of this devastating illness.

Entities:  

Keywords:  Asbestos; diagnosis; malignant pleural mesothelioma; targeted therapies; treatment

Year:  2012        PMID: 22438785      PMCID: PMC3307510     

Source DB:  PubMed          Journal:  Ochsner J        ISSN: 1524-5012


  58 in total

1.  The Mesothelioma and Radical surgery randomized controlled trial: the Mars feasibility study.

Authors:  Tom Treasure; David Waller; Carol Tan; James Entwisle; Mary O'Brien; Ken O'Byrne; Gill Thomas; Michael Snee; James Spicer; David Landau; Loïc Lang-Lazdunski; Judith Bliss; Clare Peckitt; Shaun Rogers; Erica Marriage Née Denholm; Gillian Coombes; Mark Webster-Smith; Julian Peto
Journal:  J Thorac Oncol       Date:  2009-10       Impact factor: 15.609

2.  Phase II trial of a single weekly intravenous dose of ranpirnase in patients with unresectable malignant mesothelioma.

Authors:  Stanislaw M Mikulski; John J Costanzi; Nicholas J Vogelzang; Spence McCachren; Robert N Taub; Hoo Chun; Abraham Mittelman; Timothy Panella; Carmelo Puccio; Robert Fine; Kuslima Shogen
Journal:  J Clin Oncol       Date:  2002-01-01       Impact factor: 44.544

3.  Extrapleural pneumonectomy for malignant pleural mesothelioma: outcomes of treatment and prognostic factors.

Authors:  Tristan D Yan; Michael Boyer; Mo Mo Tin; Daniel Wong; Catherine Kennedy; Jocelyn McLean; Paul G Bannon; Brian C McCaughan
Journal:  J Thorac Cardiovasc Surg       Date:  2009-03-09       Impact factor: 5.209

4.  Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.

Authors:  Herbert Hurwitz; Louis Fehrenbacher; William Novotny; Thomas Cartwright; John Hainsworth; William Heim; Jordan Berlin; Ari Baron; Susan Griffing; Eric Holmgren; Napoleone Ferrara; Gwen Fyfe; Beth Rogers; Robert Ross; Fairooz Kabbinavar
Journal:  N Engl J Med       Date:  2004-06-03       Impact factor: 91.245

5.  Potential role of histone deacetylase inhibitors in mesothelioma: clinical experience with suberoylanilide hydroxamic acid.

Authors:  Lee M Krug; Tracy Curley; Lawrence Schwartz; Stacie Richardson; Paul Marks; Judy Chiao; W Kevin Kelly
Journal:  Clin Lung Cancer       Date:  2006-01       Impact factor: 4.785

6.  US mesothelioma patterns 1973-2002: indicators of change and insights into background rates.

Authors:  Mary Jane Teta; Pamela J Mink; Edmund Lau; Bonnielin K Sceurman; Edward D Foster
Journal:  Eur J Cancer Prev       Date:  2008-11       Impact factor: 2.497

7.  An association between postoperative radiotherapy for primary breast cancer in 11 National Surgical Adjuvant Breast and Bowel Project (NSABP) studies and the subsequent appearance of pleural mesothelioma.

Authors:  Melvin Deutsch; Stephanie R Land; Mirsada Begovic; Reena Cecchini; Norman Wolmark
Journal:  Am J Clin Oncol       Date:  2007-06       Impact factor: 2.339

8.  Evaluation of 12 antibodies for distinguishing epithelioid mesothelioma from adenocarcinoma: identification of a three-antibody immunohistochemical panel with maximal sensitivity and specificity.

Authors:  Hadi Yaziji; Hector Battifora; Todd S Barry; Harry C Hwang; Carlos E Bacchi; Martin W McIntosh; Steven J Kussick; Allen M Gown
Journal:  Mod Pathol       Date:  2006-04       Impact factor: 7.842

9.  Carbon nanotubes introduced into the abdominal cavity of mice show asbestos-like pathogenicity in a pilot study.

Authors:  Craig A Poland; Rodger Duffin; Ian Kinloch; Andrew Maynard; William A H Wallace; Anthony Seaton; Vicki Stone; Simon Brown; William Macnee; Ken Donaldson
Journal:  Nat Nanotechnol       Date:  2008-05-20       Impact factor: 39.213

10.  Cisplatin and vinorelbine first-line chemotherapy in non-resectable malignant pleural mesothelioma.

Authors:  J B Sørensen; H Frank; T Palshof
Journal:  Br J Cancer       Date:  2008-06-10       Impact factor: 7.640

View more
  31 in total

1.  Racial Disparities in Treatment Patterns and Survival Among Surgically Treated Malignant Pleural Mesothelioma Patients.

Authors:  Naomi Alpert; Maaike van Gerwen; Meredith Steinberg; Nisha Ohri; Raja Flores; Emanuela Taioli
Journal:  J Immigr Minor Health       Date:  2020-12

Review 2.  Radical multimodality therapy for malignant pleural mesothelioma.

Authors:  Omar Abdel-Rahman; Zeinab Elsayed; Hadeer Mohamed; Mostafa Eltobgy
Journal:  Cochrane Database Syst Rev       Date:  2018-01-08

3.  Recent publications by ochsner authors.

Authors: 
Journal:  Ochsner J       Date:  2012

4.  Second-line gemcitabine-based chemotherapy regimens improve overall 3-year survival rate in patients with malignant pleural mesothelioma: a multicenter retrospective study.

Authors:  Hasan Mutlu; Seyda Gündüz; Halit Karaca; Abdullah Büyükçelik; Yasemin Benderli Cihan; Abdülsamet Erden; Zeki Akca; Hasan Senol Coşkun
Journal:  Med Oncol       Date:  2014-06-24       Impact factor: 3.064

5.  Malignant pleural mesothelioma: treatment patterns and humanistic burden of disease in Europe.

Authors:  Adam Moore; Bryan Bennett; Gavin Taylor-Stokes; Laura McDonald; Melinda J Daumont
Journal:  BMC Cancer       Date:  2022-06-23       Impact factor: 4.638

Review 6.  The function, mechanisms, and role of the genes PTEN and TP53 and the effects of asbestos in the development of malignant mesothelioma: a review focused on the genes' molecular mechanisms.

Authors:  Leonardo Vinícius Monteiro de Assis; Mauro César Isoldi
Journal:  Tumour Biol       Date:  2013-10-01

7.  Cancer incidence in a cohort of asbestos-exposed workers undergoing health surveillance.

Authors:  Fabiano Barbiero; Tina Zanin; Federica E Pisa; Anica Casetta; Valentina Rosolen; Manuela Giangreco; Corrado Negro; Massimo Bovenzi; Fabio Barbone
Journal:  Int Arch Occup Environ Health       Date:  2018-06-05       Impact factor: 3.015

8.  Physicochemical and pharmacokinetic properties of polymeric films loaded with cisplatin for the treatment of malignant pleural mesothelioma.

Authors:  Fabio Sonvico; Stefano Barbieri; Paolo Colombo; Claudio Mucchino; Elisabetta Barocelli; Anna Maria Cantoni; Andrea Cavazzoni; Pier Giorgio Petronini; Michele Rusca; Paolo Carbognani; Luca Ampollini
Journal:  J Thorac Dis       Date:  2018-01       Impact factor: 2.895

9.  Prognosis and prognostic factors of patients with mesothelioma: a population-based study.

Authors:  S van der Bij; H Koffijberg; J A Burgers; P Baas; M J van de Vijver; B A J M de Mol; K G M Moons
Journal:  Br J Cancer       Date:  2012-05-29       Impact factor: 7.640

10.  SMO expression level correlates with overall survival in patients with malignant pleural mesothelioma.

Authors:  Yi Zhang; Jianxing He; Fang Zhang; Hui Li; Dongsheng Yue; Changli Wang; David M Jablons; Biao He; Natalie Lui
Journal:  J Exp Clin Cancer Res       Date:  2013-02-05
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.